Galantamine (Razadyne)
Galantamine Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild-to-moderate dementia of the Alzheimer’s type | Adults | Monotherapy or adjunctive with memantine | FDA Approved |
Galantamine is distinguished from other cholinesterase inhibitors by its dual mechanism: competitive, reversible inhibition of acetylcholinesterase combined with allosteric potentiation of nicotinic acetylcholine receptors. This dual action may enhance cholinergic neurotransmission beyond simple enzyme inhibition by increasing presynaptic acetylcholine release through nicotinic receptor activation. Galantamine has demonstrated consistent efficacy across five randomised, placebo-controlled trials in patients with mild-to-moderate Alzheimer’s disease, with the effective dose range being 16–24 mg/day. It is not FDA-approved for Parkinson’s disease dementia, vascular dementia, or mild cognitive impairment (MCI).
Dementia with Lewy bodies (DLB): Open-label studies and small RCTs suggest galantamine may improve cognition and behavioural symptoms in DLB. Evidence quality: Moderate.
Vascular dementia and mixed dementia (AD + cerebrovascular disease): The GAL-INT-6 trial showed cognitive benefits in patients with vascular dementia or AD with cerebrovascular disease. Evidence quality: Moderate.
Mild cognitive impairment (MCI): Not recommended. Two 2-year MCI trials showed no efficacy benefit and a mortality signal (13 deaths on galantamine vs 1 on placebo), attributed to various vascular causes. This indication was not approved by the FDA.
Galantamine Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Alzheimer’s dementia — ER capsule initiation | 8 mg once daily (AM) | 16 mg once daily | 24 mg once daily | Increase to 16 mg after minimum 4 weeks; then to 24 mg after another 4 weeks if tolerated Administer with food; ensure adequate fluid intake |
| Alzheimer’s dementia — IR tablet initiation | 4 mg BID | 8 mg BID | 12 mg BID (24 mg/day) | Increase by 4 mg/dose every 4 weeks; give with morning and evening meals IR and ER are interchangeable at the same total daily dose |
| Switching from IR tablets to ER capsules | Same total daily dose (e.g., 8 mg BID IR → 16 mg once daily ER) | 24 mg/day | Take last IR tablet in the evening; start ER capsule the next morning | |
| Treatment interruption — restart | 8 mg/day (ER) or 4 mg BID (IR) | Re-titrate to target | 24 mg/day | If interrupted >3 days, restart at lowest dose and re-escalate Abrupt withdrawal does not increase adverse event frequency |
| Combination with memantine | Standard galantamine titration | 16–24 mg/day | 24 mg/day | Memantine does not alter galantamine pharmacokinetics; no dose adjustment needed Combination commonly used in moderate AD (FDA PI) |
Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate hepatic impairment (Child-Pugh 7–9) | 8 mg/day | 16 mg/day | 16 mg/day | Clearance ~25% lower; do not exceed 16 mg/day |
| Severe hepatic impairment (Child-Pugh 10–15) | Not recommended | No clinical data available; substantially reduced clearance expected | ||
| Moderate renal impairment (CrCl 9–59 mL/min) | 8 mg/day | 16 mg/day | 16 mg/day | AUC increased by 37–67% depending on severity; cap at 16 mg/day |
| Severe renal impairment (CrCl <9 mL/min) | Not recommended | Insufficient safety data for this population | ||
| CYP2D6 poor metabolizers or concurrent strong CYP2D6/3A4 inhibitor | 8 mg/day | Titrate cautiously | 16–24 mg/day per tolerability | CYP2D6 poor metabolizers have ~50% higher exposure (ER); paroxetine increases bioavailability ~40%; titrate based on tolerability |
The extended-release capsule provides bioequivalent exposure (AUC) to the twice-daily tablet formulation, with a lower peak concentration (~25% lower Cmax) and delayed Tmax (~4.5–5 h vs ~1 h). The smoother pharmacokinetic profile of the ER capsule, combined with once-daily dosing, may improve caregiver adherence and reduce peak-related GI side effects. Most clinicians now prefer ER as the default formulation for new starts.
Pharmacology
Mechanism of Action
Galantamine is a tertiary alkaloid originally isolated from snowdrop (Galanthus) species. It exerts its therapeutic effect through two complementary mechanisms. First, it acts as a competitive, reversible inhibitor of acetylcholinesterase (AChE), increasing the synaptic concentration of acetylcholine. Peak AChE inhibition of approximately 40% is achieved about one hour after a single 8 mg oral dose. Second, galantamine is an allosteric potentiating ligand at nicotinic acetylcholine receptors (nAChRs), binding to an allosteric site that enhances the receptor’s response to acetylcholine without directly activating it. This nicotinic modulation may amplify cholinergic neurotransmission by promoting presynaptic acetylcholine release and may also modulate the release of other neurotransmitters such as glutamate. Unlike rivastigmine, galantamine does not inhibit butyrylcholinesterase. There is no evidence that galantamine alters the underlying neurodegenerative disease process.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and complete; Tmax ~1 h (IR), ~4.5–5 h (ER); bioavailability ~90%; food reduces Cmax by 25% and delays Tmax by 1.5 h but does not affect AUC | High bioavailability ensures reliable drug delivery; administer with food to reduce GI side effects without compromising total exposure |
| Distribution | Vd 175 L; plasma protein binding 18%; blood-to-plasma ratio 1.2; 52.7% distributed to blood cells | Low protein binding minimises displacement interactions; large Vd indicates extensive tissue distribution |
| Metabolism | Hepatic via CYP2D6 (O-demethylation) and CYP3A4 (N-oxidation); also undergoes glucuronidation; ~20% excreted unchanged; linear PK over 8–32 mg/day range | Multiple metabolic pathways provide redundancy; CYP2D6 poor metabolizers have ~50% higher exposure; strong CYP2D6 or CYP3A4 inhibitors increase galantamine levels modestly (30–40%) |
| Elimination | t½ ~7 h; ~95% urine, ~5% faeces; renal clearance ~65 mL/min; total plasma clearance ~300 mL/min; ~20% excreted unchanged in urine within 24 h | Relatively short half-life supports once-daily ER dosing; significant renal component necessitates dose capping in moderate–severe renal impairment |
Side Effects
Adverse effects are predominantly cholinergic in origin and dose-related. Data below are from pooled placebo-controlled clinical trials (FDA PI Table 1, n = 3,956 galantamine vs n = 2,546 placebo). The majority of adverse reactions occurred during the dose-escalation period; the median duration of nausea was 5–7 days.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 20.7% (vs 5.5% placebo) | Most common reason for discontinuation (6.2%); dose-related; improves during maintenance; median duration 5–7 days |
| Vomiting | 10.5% (vs 2.3% placebo) | Primarily during titration; administer with food to reduce; second most common discontinuation reason |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 7.5% (vs 3.4%) | Central cholinergic effect; advise caution with driving |
| Decreased appetite | 7.4% (vs 2.1%) | Monitor weight at each visit; may compound disease-associated malnutrition |
| Diarrhea | 7.4% (vs 4.9%) | Cholinergic-mediated increase in GI motility; usually self-limiting |
| Headache | 7.1% (vs 5.5%) | Mild and transient; no specific management required |
| Decreased weight | 4.7% (vs 1.5%) | Track body weight regularly; consider nutritional supplementation if progressive |
| Fall | 3.9% (vs 3.0%) | May be related to dizziness and syncope; assess gait and fall risk |
| Abdominal pain | 3.8% (vs 2.0%) | Related to increased gastric acid secretion; consider antacid if persistent |
| Depression | 3.6% (vs 2.3%) | Distinguish from disease-related apathy; screen at follow-up visits |
| Fatigue | 3.5% (vs 1.8%) | May limit functional activities; dose-related |
| Abdominal discomfort | 2.1% (vs 0.7%) | Encourage taking with food and adequate fluid |
| Asthenia | 2.0% (vs 1.5%) | General weakness; may overlap with fatigue and malaise |
| Tremor | 1.6% (vs 0.7%) | Cholinergic origin; relevant when co-existing with parkinsonian features |
| Syncope | 1.4% (vs 0.6%) | Dose-related: 0.4% at 8 mg/day, 1.3% at 16 mg/day, 2.2% at 24 mg/day (FDA PI) |
| Somnolence | 1.5% (vs 0.8%) | Warn about driving and machinery operation |
| Bradycardia | 1.0% (vs 0.3%) | Vagotonic effect on SA/AV nodes; ECG if symptomatic |
| Dyspepsia | 1.5% (vs 1.0%) | Increased gastric acid secretion; consider PPI or H2-blocker if persistent |
| Lethargy | 1.3% (vs 0.4%) | Central cholinergic sedation; may overlap with somnolence and fatigue |
| Muscle spasms | 1.2% (vs 0.5%) | Cholinergic effect on skeletal muscle; usually mild and self-limiting |
| Malaise | 1.1% (vs 0.5%) | Non-specific; may relate to GI intolerance or anorexia |
| Laceration | 1.1% (vs 0.5%) | Likely related to falls and dizziness; assess fall risk and home safety |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Stevens-Johnson syndrome / AGEP | Very rare (post-marketing) | Days to weeks after initiation | Discontinue at first appearance of rash; do not rechallenge; seek emergency dermatological care |
| Complete AV block | Rare (post-marketing) | Any time during therapy | Immediate ECG; temporary or permanent pacing may be required; discontinue galantamine |
| Bradycardia / syncope | 1–2.2% (dose-related) | Any time; risk increases with dose | ECG monitoring; reduce dose or discontinue; assess cardiac conduction status |
| Seizures | Rare (post-marketing) | Any time | Differentiate from AD-related seizure activity; hold galantamine and evaluate |
| GI haemorrhage | Rare | Any time; higher risk with NSAIDs | Monitor for occult bleeding; discontinue if active bleed; gastroprotection with NSAIDs |
| Hepatitis / elevated liver enzymes | Rare (post-marketing) | Variable | Check LFTs; discontinue if hepatitis confirmed |
| Cholinergic crisis (overdose) | Very rare | Within hours of ingestion | IV atropine sulphate 0.5–1 mg titrated to effect; supportive care; QT prolongation and torsades de pointes reported in overdose |
| Reason for Discontinuation | Incidence (Galantamine) | Context |
|---|---|---|
| Nausea | 6.2% | vs 0.7% placebo; primarily during titration phase |
| Vomiting | 3.3% | vs <0.5% placebo; more common in women |
| Decreased appetite | 1.5% | Often accompanied by weight loss |
| Dizziness | 1.3% | Central cholinergic mechanism |
| Diarrhea | 0.8% | Usually self-limiting during dose escalation |
| Headache | 0.7% | Mild; placebo DC rate not reported at this threshold |
| Decreased weight | 0.7% | Often related to anorexia and GI intolerance |
Always administer galantamine with food and ensure adequate fluid intake. The 4-week minimum titration interval (vs weekly escalation used in early trials) was specifically adopted to reduce GI intolerance. If side effects develop, hold for several doses and restart at the same or lower dose. The ER formulation produces a lower Cmax than IR tablets and may be better tolerated in GI-sensitive patients.
Drug Interactions
Unlike rivastigmine, galantamine is metabolised by hepatic CYP enzymes (CYP2D6 and CYP3A4), making it susceptible to pharmacokinetic interactions with enzyme inhibitors. However, galantamine itself does not inhibit any major CYP isoform, so it does not increase levels of co-administered drugs. No pharmacokinetic interaction was observed with warfarin, digoxin, or memantine in dedicated studies.
Monitoring
- Cognitive functionBaseline, then every 3–6 months
RoutineUse MMSE, MoCA, or ADAS-cog to track treatment response. If no stabilisation after 3–6 months at 16–24 mg/day, reassess continuation. - Body weightEach visit during titration, then every 3 months
RoutineWeight loss (4.7% incidence) can worsen frailty and nutritional status in elderly patients. Consider dietitian referral if progressive. - GI tolerabilityEach visit during titration
RoutineAssess nausea, vomiting, diarrhea, and appetite at each dose step. Consider switching to ER formulation or reducing dose if persistent. - Heart rate & ECGBaseline; as clinically indicated
Trigger-basedVagotonic effects may cause bradycardia and AV block even in patients without known conduction disease. Obtain ECG if syncope, dizziness, or palpitations develop. Syncope risk is dose-related (2.2% at 24 mg/day). - SkinAt each visit
Trigger-basedStevens-Johnson syndrome and AGEP have been reported post-marketing. Advise patients to discontinue at first sign of rash and seek medical evaluation. - Renal functionBaseline, then annually or if clinical change
RoutineDose capped at 16 mg/day if CrCl 9–59 mL/min; not recommended if CrCl <9. Reassess if renal function declines. - Hepatic functionBaseline in at-risk patients
Trigger-basedDose capped at 16 mg/day for moderate impairment; not recommended for severe. Post-marketing hepatitis reports warrant vigilance.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to galantamine hydrobromide or any excipient in the formulation
Relative Contraindications (Specialist Input Recommended)
- Sick sinus syndrome or AV block: Vagotonic effects may worsen bradycardia; cardiology input required before initiation
- Active peptic ulcer disease or GI bleeding: Increased gastric acid secretion may worsen mucosal injury
- Severe hepatic impairment (Child-Pugh 10–15): Use is not recommended; no dosing data available
- Severe renal impairment (CrCl <9 mL/min): Use is not recommended
Use with Caution
- Asthma or COPD: Cholinergic stimulation may cause bronchoconstriction; monitor respiratory function
- Bladder outflow obstruction: Cholinomimetics may exacerbate urinary retention
- History of seizures: Cholinesterase inhibitors have theoretical proconvulsant potential
- Concurrent NSAID use: Monitor for GI bleeding; gastroprotection recommended
- Planned surgery requiring anaesthesia: Inform anaesthetist; galantamine may potentiate succinylcholine-type muscle relaxants
- Concurrent strong CYP2D6 or CYP3A4 inhibitors: Monitor for increased galantamine side effects
In two 2-year, placebo-controlled MCI trials, 13 patients on galantamine (n = 1,026) and 1 patient on placebo (n = 1,022) died. Deaths were due to various causes including myocardial infarction, stroke, and sudden death. The mortality imbalance was statistically significant. Galantamine is not approved for MCI and should not be used in this population. This mortality signal was not replicated in Alzheimer’s disease trials where the placebo mortality rate numerically exceeded the galantamine rate.
Post-marketing reports of Stevens-Johnson syndrome (SJS) and acute generalised exanthematous pustulosis (AGEP) have been received. Therapy should be discontinued at the first appearance of any skin rash, unless it is clearly unrelated to the drug. If signs or symptoms suggest a serious skin reaction, galantamine should not be resumed and alternative therapy should be considered.
Patient Counselling
Purpose of Therapy
Galantamine is prescribed to help preserve memory, thinking ability, and the capacity to manage daily activities in people with Alzheimer’s disease. It works by increasing levels of a chemical messenger called acetylcholine in the brain and by enhancing the activity of certain brain receptors (nicotinic receptors). It does not cure the underlying disease but may slow the rate of cognitive decline. Caregivers play a central role in ensuring the medication is taken correctly and in monitoring for side effects.
How to Take
ER capsules: Take once daily in the morning with food. Swallow whole; do not crush or chew. IR tablets: Take twice daily with morning and evening meals. Oral solution: Measure dose using the provided syringe; may be mixed with a small glass of water, juice, or soda. Ensure adequate fluid intake throughout the day.
Sources
- Razadyne ER (galantamine extended-release capsules) — FDA-approved Prescribing Information. Janssen Pharmaceuticals. Revised September 2022. accessdata.fda.govPrimary source for ER capsule dosing, adverse reactions (Table 1, pooled n=3,956), pharmacokinetics, drug interactions, and MCI mortality warning.
- Razadyne/Razadyne ER (galantamine hydrobromide tablets, oral solution, ER capsules) — FDA-approved Prescribing Information. Revised 2017. accessdata.fda.govComprehensive label covering all formulations; source for IR tablet dosing and historical adverse event data.
- Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension (GAL-USA-1). Neurology. 2000;54(12):2261–2268. doi:10.1212/wnl.54.12.2261Pivotal 6-month RCT (n=636) demonstrating 3.8–3.9 point treatment effect on ADAS-cog at 24 and 32 mg/day; with 6-month open-label extension.
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD (GAL-USA-10). Neurology. 2000;54(12):2269–2276. doi:10.1212/wnl.54.12.2269Key trial (n=978) using slow 4-week dose escalation; demonstrated 3.3–3.6 point ADAS-cog benefit at 16 and 24 mg/day with improved tolerability.
- Wilcock GK, Lilienfeld S, Gaens E; Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ. 2000;321(7274):1445–1449. doi:10.1136/bmj.321.7274.1445International 6-month trial (n=653) confirming ~3-point ADAS-cog treatment effect; demonstrated cognitive, functional, and global benefits.
- Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71(5):589–595. doi:10.1136/jnnp.71.5.589Flexible-dose trial supporting the clinical utility of individually titrated galantamine; Goal Attainment Scaling was used as a secondary outcome.
- Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61(2):252–256. doi:10.1001/archneur.61.2.25236-month open-label extension demonstrating sustained cognitive benefits on ADAS-cog/11 with continuous galantamine 24 mg/day.
- Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39–47. doi:10.1016/S1474-4422(08)70261-3RCT in severe AD; showed some cognitive benefit but no significant functional improvement; extends safety data beyond mild-moderate population.
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management, and support for people living with dementia and their carers. NICE guideline [NG97]. 2018 (updated 2023). nice.org.uk/guidance/ng97UK guideline recommending AChE inhibitors (donepezil, galantamine, rivastigmine) as first-line pharmacotherapy for mild-to-moderate AD.
- Samochocki M, Höffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003;305(3):1024–1036. doi:10.1124/jpet.102.045773Establishes galantamine’s allosteric potentiating ligand activity at nicotinic receptors, the pharmacological basis for its dual mechanism.
- Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5(2):115–124. doi:10.2174/157488410791110805Comprehensive PK review covering absorption, distribution, metabolism, elimination, and effects of CYP2D6 polymorphism on galantamine exposure.
- Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383–1392. doi:10.2165/00003088-200342150-00005Detailed PK characterisation including hepatic and renal impairment data, drug-drug interactions, and population pharmacokinetics.